Skip to main content
Premium Trial:

Request an Annual Quote

Micromet Licenses Single-Chain Antibody Technology to EvoGenix

NEW YORK, Dec.23 (GenomeWeb News) - Micromet of Munichhas licensed its single-chain antibody technology to Sydney-based EvoGenix, the companies said today.


The technology is owned by both Micromet and Enzon Pharmaceuticals. Under the agreement, EvoGenix will apply the technology, in combination with its own, to generate and optimize antibodies for use in diagnostic or therapeutic products.


Micromet will receive an upfront payment, as well as annual maintenance and sublicensing fees, which it will share with Enzon.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.